Het onderzoek wordt bij gezonde personen uitgevoerd. Uitkomsten uit deze lijn van onderzoek bieden nieuwe handvaten voor verklaringsmodellen en therapeutische interventies voor aandoeningen waarbij een verandering in de functie van het endocriene systeem optreedt. not applicable
Conditions
Interventions
In the experimental group, participants will receive a 24 IU dose of oxytocin
via a nasal spray during the acquisition phase and an identically looking
placebo nasal spray during the evocation phase
Sponsors
Universiteit Leiden
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: healthy, female, premenopausal, 18-35 years old, right-handed, using oral contraceptives
Exclusion criteria
Exclusion criteria: Somatic and/or psychiatric conditions, (intendend) pregnancy or breast-feeding, heavy use of (illegal) drugs including cannabis and habits of heavy drinking, known sensitivity or hypervigilance to one of the ingredients of the oxytocin or the odor used in this experiment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main study parameter is salivary oxytocin level during evocation in the experimental group compared to the placebo group. Oxytocin will be measured four times during the first two evocation sessions (once before and in 5, 20 and 30 after the drug or placebo administration) and twice during the third evocation day. | — |
Secondary
| Measure | Time frame |
|---|---|
| Additional study parameters assessed at baseline and at the evocation phase are: salivary cortisol, pain sensitivity and during the third evocation day only, resting state and task-related (emotional faces, infant crying, and pain stimulation) brain activity, pain sensitivity levels and physiological data using the nociceptive level index during thermal pain stimulation. Additionally, to explore the possible influence of genotype on the effects of conditioning, the 5-HTTLPR genotype and other candidate genotypes will be assessed in saliva. | — |
Countries
Netherlands
Outcome results
None listed